Treatment of growth failure associated with CRI
Short stature associated with chronic renal insufficiency may be treated with injections of growth hormone up until the time of kidney transplantation.
If a kidney transplant is being considered in the future, an important goal of growth hormone treatment is to optimize your child's height before transplantation, because some of the medication that must be taken after a kidney transplant can interfere with growth.
Genentech products approved for the treatment of growth failure associated with CRI
Nutropin AQ and Nutropin are two forms of growth hormone available from Genentech's family of products. These two products are indicated for the treatment of growth failure associated with CRI, up to the time of kidney transplantation. Nutropin AQ and Nutropin therapy should be used in conjunction with optimal management of CRI.To learn more, click on the names of the products below—you may want to discuss them with your healthcare provider.
Nutropin AQ Pen 10 for use with Nutropin AQ Pen 10 Cartridge: The latest innovation from Genentech's growth hormone product line, the Nutropin AQ Pen 10 offers simple delivery of Nutropin AQ, convenient transport, and enhanced safety features. Nutropin AQ Pen 10 is available in the U.S. by prescription only.
Nutropin AQ: A liquid GH that is premixed and ready for immediate injection. Unlike lyophilized (powdered) forms of GH, no mixing is necessary. Nutropin AQ makes GH therapy easier by eliminating about half the steps required to prepare lyophilized GH.
Nutropin: A lyophilized powder formulation that is reconstituted, or mixed, with Bacteriostatic water prior to an injection.
You should consult with your healthcare provider about the benefits and risks of GH therapy.
See Complete Indications and Important Safety Information
Back to top
